Sabin PDP
Through rigorous vaccine research and development (R&D), the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) is creating an environment that can support the introduction of and ready access to new vaccine products when they become available. And through its advocacy work, the Sabin PDP is working to put neglected tropical diseases (NTDs) – and the need to control and eliminate them – more prominently onto the global health and vaccine development agenda. Coalitions worldwide are adopting the Sabin PDP’s messaging and educating funders and policymakers about the need to develop these vaccines.
The Sabin PDP’s most advanced project, the Human Hookworm Vaccine Initiative (HHVI), builds on more than 14 years of research. This program is developing vaccine candidates alongside partners in endemic countries such as Brazil and Gabon, as well as in Europe and Australia. This large, interdisciplinary collaboration includes clinical, basic and translational scientists, not only focused on advancing safe, effective vaccines, but also building expertise and capacity for vaccine development among R&D institutions in other countries with the goal of developing sustainable industrial production of vaccines in endemic countries.
Sabin is addressing the threat of NTDs, such as hookworm, worldwide through rigorous R&D.
In 2013, the Sabin PDP continued Phase 1 clinical trials at a field site in Brazil evaluating the safety and efficacy of Na-GST-1, one of our hookworm vaccine candidates. We also began Phase 1 clinical trials for Na-GST-1, as well as a second hookworm vaccine candidate, Na-APR-1, in Washington, DC. Funding from the Michelson Medical Research Foundation is supporting the discovery of additional antigens to prevent hookworm and other intestinal helminths. Through our new collaboration with the HOOKVAC Consortium, we are working to expand manufacturing efforts in Europe, as well as clinical trials in Gabon, to prevent human hookworm.
15